Skip to main content
. 2019 Jan 24;24(7):893–900. doi: 10.1634/theoncologist.2018-0407

Figure 4.

image

Everolimus PFS benefit based on subtype classification. (A): HER2‐enriched versus non‐HER2‐enriched subgroups. (B): Luminal (including normal‐like) versus nonluminal subgroups.

Abbreviations: CI, confidence interval; HER2, human epidermal growth factor receptor 2; PFS, progression‐free survival.